Clinical characteristics of 361 patients older than 60 with AML
Characteristic . | Value . |
---|---|
No. of female patients (%) | 166 (46) |
Median age, y (range) | 67 (61-84) |
Disease status, no. of patients (%) | |
De novo AML | 231 (64) |
M0 | 13 (6) |
M1 | 40 (17) |
M2 | 66 (29) |
M3 | 13 (6) |
M4 | 53 (23) |
M5 | 22 (10) |
M6 | 3 (1) |
M7 | 1 (0) |
Missing | 20 (9) |
Secondary AML | 119 (33) |
Preceding MDS | 78 (22) |
Preceding malignancy | 41 (11) |
Missing | 11 (3) |
Median hemoglobin level, g/L | 91 (38-172) |
Missing, no. of patients (%) | 17 (5) |
Median platelet count, × 109/L (range) | 61.5 (4-848) |
Missing, no. of patients (%) | 17 (5) |
Median WBC count, × 109/L (range) | 8.4 (0.2-303) |
Missing, no. of patients (%) | 16 (4) |
Median PB blasts, % (range) | 31 (0-100) |
Missing, no. of patients (%) | 66 (18) |
Median BM blasts, % (range) | 70 (0-100) |
Missing, no. of patients (%) | 55 (15) |
Median LDH level, U/L (range) | 358 (57-6623) |
Missing, no. of patients (%) | 32 (9) |
Lymphadenopathy, no. of patients (%) | 46 (13) |
Missing | 42 (12) |
Gum hypertrophy, no. of patients (%) | 14 (4) |
Missing | 28 (8) |
Extramedullary involvement, no. of patients (%) | 16 (4) |
Missing | 37 (10) |
Characteristic . | Value . |
---|---|
No. of female patients (%) | 166 (46) |
Median age, y (range) | 67 (61-84) |
Disease status, no. of patients (%) | |
De novo AML | 231 (64) |
M0 | 13 (6) |
M1 | 40 (17) |
M2 | 66 (29) |
M3 | 13 (6) |
M4 | 53 (23) |
M5 | 22 (10) |
M6 | 3 (1) |
M7 | 1 (0) |
Missing | 20 (9) |
Secondary AML | 119 (33) |
Preceding MDS | 78 (22) |
Preceding malignancy | 41 (11) |
Missing | 11 (3) |
Median hemoglobin level, g/L | 91 (38-172) |
Missing, no. of patients (%) | 17 (5) |
Median platelet count, × 109/L (range) | 61.5 (4-848) |
Missing, no. of patients (%) | 17 (5) |
Median WBC count, × 109/L (range) | 8.4 (0.2-303) |
Missing, no. of patients (%) | 16 (4) |
Median PB blasts, % (range) | 31 (0-100) |
Missing, no. of patients (%) | 66 (18) |
Median BM blasts, % (range) | 70 (0-100) |
Missing, no. of patients (%) | 55 (15) |
Median LDH level, U/L (range) | 358 (57-6623) |
Missing, no. of patients (%) | 32 (9) |
Lymphadenopathy, no. of patients (%) | 46 (13) |
Missing | 42 (12) |
Gum hypertrophy, no. of patients (%) | 14 (4) |
Missing | 28 (8) |
Extramedullary involvement, no. of patients (%) | 16 (4) |
Missing | 37 (10) |
Subheadings under “De novo AML” refer to FAB subtypes. Percentages may not add to 100 because of rounding. MDS indicates myelodysplastic syndrome.